SEC Filings
ARK Reports About 7% Of Absci — Its Stake Carries No Control Aim
ARK Genomic Revolution ETF was the only client with an interest above 5% in the reported shares.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
SEC Filings
ARK Genomic Revolution ETF was the only client with an interest above 5% in the reported shares.
SEC Filings
ARK Innovation ETF was the client identified as holding an interest above 5% in the reported shares.
SEC Filings
The September 30 position covers 20,508,004 shares and was jointly reported by ARK and its chief executive.
SEC Filings
The insurer set December 23, 2026, as the record date for its next cash payout.
SEC Filings
The investment manager and Catherine D. Wood reported the same shares, with different voting and disposal powers.
SEC Filings
The investment manager's report covered 1,913,123 common shares held as of September 30.
SEC Filings
Catherine D. Wood reported shared voting authority over the same position in the cancer-testing company.
SEC Filings
The investment manager's September 30 position covered 44,745,024 shares in the AI drug developer.
SEC Filings
The investment manager reported more than 10 million shares in the developer of DNA-editing medicines.
SEC Filings
The new securities carry a 7.625% rate, while the older series targeted for repurchase carries 6.000%.
SEC Filings
The investment advisers and their managing partner reported authority over shares directly owned by advisory clients.
SEC Filings
Corbus is advancing a late-stage cancer trial alongside an early-stage obesity drug study.